

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Jean-Louis Imbach et al.

Serial No.:

09/883,033

Filed:

June 15, 2001

Title:

3'-Prodrugs of 2'-Deoxy-β-L-Nucleosides

Assistant Commissioner for Patents Washington, DC 20231

RECEIVED

MAY 1 4 2003

TECH CENTER 1600/2900

April 30, 2003

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Dear Sirs,

In response to the Restriction Requirement mailed on December 31, 2002, please amend the above-identified application as follows.

In the Claims

Please cancel claims 210-241.

Remarks

In the Office Action dated December 31, 2002, the Examiner, under 35 U.S.C.§ 121, restricted the invention into the following three groups.

- Group I -- Claims 156, 163, 175-209 drawn to 3' amino acid substituted pyrimidine compounds/compositions, classified in class 536, subclass 28.4.
- Group II-- Claims 219-231 drawn to 3'-amino acid substituted pyrimidine compositions in combination with one or more anti-hepatitis B virus agents, classified in class 514, subclass 49, 894.
- Group III -- Claims 232-245 drawn to 3'-amino acid substituted pyrimidine compositions in various delivery forms, classified in class 514, subclass 49+ and class 424, subclass 464.



CERTIFICATE OF MAILING UNDER 37 CFR § 1.8 (a)

I hereby certify that this Response to Restriction Requirement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

MAY 1 4 2003

TECH CENTER 1600/2900

Date: April 30, 2003